A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Hackensack Meridian Health
University Hospital, Caen
Medical University of South Carolina
Fate Therapeutics
Center for International Blood and Marrow Transplant Research
Merck Sharp & Dohme LLC
Masonic Cancer Center, University of Minnesota
Allogene Therapeutics
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Dartmouth-Hitchcock Medical Center
Dana-Farber Cancer Institute
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Center for International Blood and Marrow Transplant Research
Imugene Limited
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
French Innovative Leukemia Organisation
Case Comprehensive Cancer Center
Thomas Jefferson University
Dana-Farber Cancer Institute
Sana Biotechnology
University of Maryland, Baltimore
Center for International Blood and Marrow Transplant Research
Masonic Cancer Center, University of Minnesota
Case Comprehensive Cancer Center
University Health Network, Toronto
Mayo Clinic
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
German CLL Study Group
German CLL Study Group
Cedars-Sinai Medical Center
University Hospital Heidelberg
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
M.D. Anderson Cancer Center
Gilead Sciences
Fate Therapeutics
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center